Prolacta Bioscience Closes Series D
Prolacta Bioscience, maker of nutritional products designed for critically ill, premature infants in neonatal intensive care units, has closed on an undisclosed amount of Series D financing from Health Evolution Partners. The money will be used to bolster sales, among other expansion efforts. Prolacta is based in Monrovia, Calif.
3 November 2011•5 mins read
